Efficacy of eculizumab in refractory life-threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia

Anne-Cécile Gauchy; Maxime Hentzien; Alain Wynckel; Victoire de Marcellus; Cyrielle Rodier; Alain Delmer; Anne Quinquenel

doi:10.1002/ccr3.3250

Efficacy of eculizumab in refractory life-threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia

Clin Case Rep. 2020 Aug 17;8(12):2641-2644. doi: 10.1002/ccr3.3250. eCollection 2020 Dec.

Authors

Anne-Cécile Gauchy^{1

2}, Maxime Hentzien^{2

3}, Alain Wynckel⁴, Victoire de Marcellus^{1

2}, Cyrielle Rodier^{1

2}, Alain Delmer^{1

2}, Anne Quinquenel^{1

2}

Affiliations

¹ Service d'Hématologie Clinique Hôpital Robert Debré Centre Hospitalier Universitaire Reims France.
² UFR Médecine Université Reims Champagne-Ardenne Reims France.
³ Service de Médecine Interne Maladies Infectieuse et Immunologie Clinique Hôpital Robert Debré Centre Hospitalier Universitaire Reims France.
⁴ Service de Néphrologie Hôpital Robert Debré Centre Hospitalier Universitaire Reims France.

Abstract

Eculizumab may be considered as an emergency therapeutic option in refractory life-threatening warm autoimmune hemolytic anemia especially if direct antiglobulin test is positive for both IgG and C3d and after failure of all conventional treatments.

Keywords: chronic myelomonocytic leukemia; eculizumab; warm autoimmune hemolytic anemia.

Publication types

Case Reports